CRISPR Therapeutics

[CRISPR Therapeutics @CRISPRTX]

May is #NationalCancerResearchMonth, highlighting the critical role of research in advancing cancer prevention, diagnosis, and treatment. We recognize all of the individuals working tirelessly to improve cancer outcomes. Learn more from @AACR: https://t.co/RQPsJN3Qfv

[CRISPR Therapeutics @CRISPRTX]

May is #LupusAwarenessMonth, a time to increase awareness of lupus, an autoimmune disease that affects many parts of the body and impacts daily life. Learn more from @LupusOrg: https://t.co/3C1GdvQBZU

[CRISPR Therapeutics @CRISPRTX]

Today is #InternationalThalassemiaDay. Living with #thalassemia, an inherited #BloodDisorder, can involve ongoing medical care, including monitoring and blood transfusions. We recognize the patients and families affected by thalassemia. Learn more: https://t.co/o2e999ppOc

[CRISPR Therapeutics @CRISPRTX]

Today, we announced our first quarter earnings results. Read more about our recent highlights and outlook: https://t.co/uX1W4fTDqy #CRSP

[CRISPR Therapeutics @CRISPRTX]

Congrats Kathy High, MD, a member of our Board, and Stu Orkin, MD, on the Breakthrough Prize in Life Sciences. Stu's BCL11A discovery paved the way for the 1st CRISPR-based therapy, which we pioneered for SCD and TDT. Congrats to all the 2026 laureates! https://t.co/4144jw5Blk

[CRISPR Therapeutics @CRISPRTX]

March 24 is Lipoprotein(a) Awareness Day. Elevated Lp(a) is an inherited, often under-recognized cardiovascular risk factor. Today we recognize the importance of awareness and education to #KnowLpa. Learn more from the @FamilyHeartFdn: https://t.co/z034Ysfloh

[CRISPR Therapeutics @CRISPRTX]

Today, we announced our fourth quarter and full year earnings results. Read more about our recent highlights and outlook: https://t.co/MBf204aTfF

[CRISPR Therapeutics @CRISPRTX]

We’re entering the year with strong momentum across the pipeline. Today’s update outlines our strategic priorities and anticipated milestones. Learn more here: https://t.co/G2XfOropsg

[CRISPR Therapeutics @CRISPRTX]

CRISPR Therapeutics will present at the 44th Annual #JPM2026 Healthcare Conference on Jan. 12th at 8:15 a.m. PT. A live webcast and replay will be available on our website.
https://t.co/WQOLBMlxpG

[CRISPR Therapeutics @CRISPRTX]

Today, we shared a clinical update on zugo-cel (formerly known as CTX112™), reflecting continued progress across autoimmune disease and hematologic malignancies. Learn more here: https://t.co/eYb2rDwtKv

[CRISPR Therapeutics @CRISPRTX]

Today, we report financial results and business highlights for the third quarter 2025. Read more: https://t.co/8hnxiHd9JO

[CRISPR Therapeutics @CRISPRTX]

We announced positive late-breaking Phase 1 data for CTX310 at #AHA25, demonstrating deep and durable ANGPTL3 editing with lowering of triglyceride and lipid levels, published in @NEJM.
A major milestone for our in vivo gene-editing platform. https://t.co/gNfsO9kBW8

[CRISPR Therapeutics @CRISPRTX]

We’re proud to share new preclinical data from our novel SyNTase™ gene editing platform for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). The data are featured in an oral presentation at the ESGCT 2025 Annual Congress: https://t.co/1UZpJhWN8J #ESGCT2025

[CRISPR Therapeutics @CRISPRTX]

We’re excited to announce an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2025 Congress. The presentation will introduce our novel SyNTase™ gene editing technology & its application in single-dose in vivo gene correction: https://t.co/rEVNJND76O

[CRISPR Therapeutics @CRISPRTX]

In recognition of #WorldHeartDay, we are raising awareness of the impact of #CardiovascularDisease. According to the CDC, in 2023, one out of every three deaths in the U.S. could be attributed to cardiovascular disease. Find more #CVD statistics here: https://t.co/daSmfIoDqg

[CRISPR Therapeutics @CRISPRTX]

Today is #FamilialHypercholesterolemia (FH) Awareness Day. This day aims to raise awareness of #FH, a common genetic condition that causes high levels of LDL cholesterol, which increases the chance of developing coronary artery disease: Learn more: https://t.co/apR7JcWfdb #KnowFH

[CRISPR Therapeutics @CRISPRTX]

Today, we announced with Sirius Tx that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a next-generation, long-acting Factor XI siRNA for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty: https://t.co/n0ta8vpWLH

[CRISPR Therapeutics @CRISPRTX]

This Sunday, September 21st, is #WorldMyositisDay. #Myositis is an autoimmune disease that causes inflammation of the body's muscles and impacts movement. Learn more about this condition at: https://t.co/iiuhx7bv2l

[CRISPR Therapeutics @CRISPRTX]

Momentum is building around in vivo gene editing’s potential to significantly impact cardiovascular disease. @ARKInvest highlighted our investigational programs and the opportunity to make a meaningful difference in people’s lives. Read the article here: https://t.co/SdiLmhLNWk

[CRISPR Therapeutics @CRISPRTX]

We’re excited to announce the acceptance of two late-breaking data presentations at the upcoming American Heart Association (AHA) Scientific Sessions 2025, taking place November 7-10 in New Orleans.

Learn more here: https://t.co/OR767phik9 @AHAScience #AHA25